Paul Mampilly Has Identified The Next Medical Revolution

When someone claims to have pinpointed the next area of medical revolution, people can become understandably skeptical when these statements are made. However, Paul Mampilly is gaining the attention of the general public with his recent proclamations and he does not appear to be ready to let go anytime soon. Follow Paul Mampilly on Stocktwits.com.

He threw out a series of hints about the company in question and while these hints were cryptic in nature, experienced observers did not need long to find out more. The breakthrough that he referenced is believed to eliminate one of the most incurable health issues that people face today.

This billion dollar company exists in the world of precision medicine, where a doctor is able to look directly into the person’s DNA and provide a specific diagnosis. The medicine can then be designed to match the person’s exact genetic makeup and serve as a suit of armor over the long haul.

Judging from the clues that have been provided, Paul Mampilly is referring to Myriad Genetis. The company is located in Salt Lake City, Utah. The company offers personalized forms of medicine and they are currently providing patients with tests that are designed to assess their level of cancer risk.

Cancer testing is the main driver of revenue for the company at this point in time. These tests are referred to as a form of hereditary screening and they help patients to identify their risk factors. Paul Mampilly is quick to remind would be investors that Myriad Genetis stock has been increasing in value over the course of the past year.

Learn: http://www.talkmarkets.com/contributor/Paul-Mampilly/

In fact, Paul Mampilly’s recommendations took place before the stock price even began to rise. The stock has gone from $1.5 billion last summer to over $2 billion currently. Myriad is the current leader in this particular field and this bodes well for those who are in search of a proper investment that can function as a buy and hold option.

While no one can ever say with any certainty that a stock will perform to its fullest potential, there is also the chance that Myriad Genetis could become a form of default testing in the future. While Foundation Medicine is making a push in the same direction, Paul Mampilly believes that Myriad Genetis is the wave of the future. By all accounts, they are certainly poised to take over the nascent personalized medicine industry and their future is incredibly bright. Visit stockgumshoe.com to know more.